Nanocarrier Property Prediction for Payload-Independent Formulation Screening

The patent extracts and removes payload-specific features from the prediction model inputs, retaining only nanocarrier formulation features (peptide sequence, lipid composition, ratios, molecular weights). This extraction allows the model to predict nanocarrier properties universally across different payloads and applications, resolving the contradiction between prediction accuracy for specific cases and general model universality.

The patent creates a universal prediction model that can accurately predict nanocarrier properties (transfection efficiency, cellular uptake, cytotoxicity) across multiple different payloads and applications without requiring payload-specific training. This multi-functionality approach allows a single model to serve diverse purposes, from gene therapy to cancer treatment, thereby achieving both accuracy and versatility.

The patent performs preliminary computational characterization of nanocarrier formulations using machine learning predictions before conducting actual experimental testing. By pre-screening candidate formulations in silico to identify promising candidates with desired properties (high transfection efficiency, low cytotoxicity), the approach reduces the number of experiments needed, thereby saving time and resources while maintaining reliability through experimental validation of top candidates.

The patent creates a virtual copy of the nanocarrier system through computational models that replicate and predict the behavior of physical nanocarrier formulations. This in silico modeling allows extensive characterization and optimization without requiring proportional physical experimentation, significantly reducing the time and resources needed while maintaining predictive reliability through careful model training on experimental data.

The patent applies preliminary computational screening using machine learning models to evaluate and rank potential nanocarrier formulations before actual preparation and testing. By pre-calculating predicted properties (transfection efficiency, cellular uptake, cytotoxicity) for multiple formulation variants, the approach identifies optimal candidates in silico, reducing the need to physically prepare and test all possible formulations, thereby lowering costs and complexity while maintaining thorough optimization.

The patent creates computational representations (digital twins) of nanocarrier formulations that can be extensively analyzed and compared without physical manufacturing. These virtual models allow exploration of the design space through simulation and prediction, enabling identification of optimal formulations through iterative optimization in silico before physical production, thereby reducing the actual formulation and testing complexity required.